Side-by-side comparison of AI visibility scores, market position, and capabilities
Boston biopharma AI platform automating competitive landscape, regulatory intelligence, and clinical research for DayOne and ZS Associates; YC $3.1M Pags/Splash seed competing with Citeline and Evaluate for AI-powered pharma knowledge work.
Maven Bio is a Boston, Massachusetts-based AI platform for biopharma knowledge work — backed by Y Combinator with $3.1 million in seed funding led by Pags Group, Splash Capital, and NVO Group with YC participation, following a $500,000 pre-seed from YC in September 2023 — providing biopharma companies, consultancies, and investors with domain-specific AI modules built on curated biopharma industry data that automate the research, analysis, and synthesis tasks that pharmaceutical knowledge workers perform manually. Founded in 2023 by Michael Brady and Arjun Murthy and operating with an 8-person team in Boston, Maven Bio serves customers including DayOne and ZS Associates (the global biopharma consulting firm) with a platform that converts biopharma questions into decisions faster through AI-powered access to curated drug development, clinical, and regulatory knowledge.
Dominant browser-based collaborative UI design platform at ~$600M ARR and $12.5B valuation; Adobe's $20B acquisition blocked by regulators in 2023, Figma remains independent competing with Sketch and Adobe.
Figma is a San Francisco-based collaborative web-based product design platform that has become the dominant tool for UI/UX designers and product teams — enabling real-time multi-user collaboration on interface design, prototyping, and design system management directly in the browser without installing desktop software. Founded in 2012 by Dylan Field and Evan Wallace and backed by Sequoia, Greylock, and Andreessen Horowitz with over $330 million raised, Figma generated approximately $600 million in ARR in 2023, serving 4 million+ designers and product teams at companies including Microsoft, Airbnb, Twitter, and Uber. Adobe announced a $20 billion acquisition offer in 2022, which was blocked by regulators in 2023 — Figma remains independent.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.